Search

Natera Inc

Закрыт

СекторЗдравоохранение

366.16 6.51

Обзор

Изменение цены акций

24 ч

Текущая

Мин.

343.79

Макс.

366.38

Ключевые показатели

By Trading Economics

Доход

18M

-67M

Продажи

56M

753M

Прибыль на акцию

-0.47

Рентабельность продаж

-8.897

Сотрудники

6,135

EBITDA

20M

-45M

Рекомендации

By TipRanks

Рекомендации

Активная покупка

Прогноз на 12 месяцев

+1.14% upside

Дивиденды

By Acuity

Следующий отчет о доходах

5 нояб. 2026 г.

Рыночная статистика

By TradingEconomics

Рыночная капитализация

11B

49B

Предыдущая цена открытия

359.65

Предыдущая цена закрытия

366.16

Новостные настроения

By Acuity

19%

81%

23 / 339 Рейтинг в Healthcare

Natera Inc График

Прошлые результаты не являются надежным индикатором будущих результатов.

Связанные новости

16 сент. 2026 г., 19:07 UTC

Natera Inc shares fell modestly lower, reaching a notable low today, though remaining above their 20-day moving average.

15 сент. 2026 г., 23:01 UTC

Natera Inc shares are higher in after-market hours following Tuesday's close, continuing a trend of four consecutive sessions that also closed higher.

14 сент. 2026 г., 19:26 UTC

News
Social Media

Natera Inc is gaining momentum as it breaks above September's value area. UBS raised its price target while maintaining a "buy" rating.

11 сент. 2026 г., 22:51 UTC

Natera Inc shares are lower in after-market hours, with no specific news identified to explain the movement. Broader market sentiment may be influencing trading.

9 сент. 2026 г., 20:07 UTC

News

UBS has raised its price target on Natera Inc. to $435, maintaining a Buy rating and contributing to a rise in shares during Wednesday's session.

8 сент. 2026 г., 23:06 UTC

Natera Inc. shares are higher in after-market trading, maintaining upward momentum since Tuesday's close despite an earlier pullback. The stock is above its 20-day moving average.

3 сент. 2026 г., 19:36 UTC

News

Baird raised Natera's price target to $376 from $348, maintaining an Outperform rating. Shares are higher since Wednesday's close amid easing interest rate concerns.

2 сент. 2026 г., 23:26 UTC

Natera Inc. shares are higher in after-market trading, continuing a strong performance over the past month, well above the 20-day moving average.

1 сент. 2026 г., 19:36 UTC

News
Event

Natera's Signatera test shows 100% predictive value for lymphoma treatment responses, boosting shares higher during Tuesday's session.

31 авг. 2026 г., 23:01 UTC

Natera Inc shares are higher in after-market trading, stabilizing near earlier highs amid broader economic concerns over potential interest rate hikes.

28 авг. 2026 г., 20:02 UTC

News

Natera Inc partners with Susan G. Komen to enhance breast cancer education. Shares are lower amid high trading volume and broader market pressures.

27 авг. 2026 г., 20:07 UTC

News

Natera partners with Angiex to use Signatera in a Phase I trial for AGX101, aimed at enhancing cancer treatment response evaluation. Shares are roughly flat.

26 авг. 2026 г., 19:26 UTC

Natera Inc's shares are higher today, reflecting a general market uptrend. The stock remains above its 20-day moving average and near a one-month high.

24 авг. 2026 г., 19:46 UTC

Natera Inc shares are lower today, pulling back from earlier session highs. Rising oil prices and geopolitical tensions impact overall market sentiment.

21 авг. 2026 г., 20:06 UTC

Natera Inc shares are higher today, rebounding from an early dip amid positive momentum in the biotechnology sector and overall market performance.

20 авг. 2026 г., 23:16 UTC

Natera Inc. shares are slightly higher in after-market hours, remaining near the upper end of their one-month range amid broader market pressure from rising yields.

19 авг. 2026 г., 20:02 UTC

Natera Inc shares are higher today amid a broader market rally, with notably increased trading volume indicating heightened investor interest.

18 авг. 2026 г., 23:36 UTC

Natera Inc shares are lower in after-market hours, with no specific news identified. Broader market sentiment is impacted by declines in the Nikkei 225 Index.

17 авг. 2026 г., 19:36 UTC

Social Media
News

Natera Inc reports second-quarter revenue of $752.8 million, exceeding expectations. Shares are higher as the company cites strong test volume growth and regulatory approvals.

13 авг. 2026 г., 19:26 UTC

News
Event

Natera Inc is trading lower despite announcing a collaboration on a Phase 1 clinical trial and exceeding second-quarter expectations by $100 million.

12 авг. 2026 г., 20:06 UTC

News
Event

Natera Inc shares are rising after analyst upgrades and support for a Phase 1 trial in Germany using its Latitude assay to monitor tumor DNA.

11 авг. 2026 г., 20:02 UTC

News

Natera Inc reported strong Q2 revenue of $752.8 million but shares are lower amid concerns over significant insider selling.

10 авг. 2026 г., 20:02 UTC

News
Social Media

Natera Inc shares are lower amid negative sentiment from insider selling, despite recent analyst upgrades and price target increases from Morgan Stanley and Barclays.

7 авг. 2026 г., 20:03 UTC

Social Media
News

Natera Inc. shares rise sharply after analyst upgrades and strong earnings. RBC Capital raised its price target to $350, citing robust revenue growth.

6 авг. 2026 г., 23:02 UTC

Social Media
News

Natera Inc reported second-quarter revenue of $752.8 million, exceeding expectations. The stock is trading higher after the market closed, following strong earnings results.

5 авг. 2026 г., 23:01 UTC

Event

Natera Inc announced an application for the Signatera test in Japan. Shares are trading lower in after-market hours following the announcement.

4 авг. 2026 г., 19:04 UTC

Natera Inc shares are rising amid a broader market rally and high trading volume, despite challenges from declining U.S. factory orders and falling oil prices.

3 авг. 2026 г., 19:23 UTC

News

Natera Inc. shares are higher today, reflecting broader market gains amid strong manufacturing data and significant increases in major technology stocks.

31 июл. 2026 г., 19:46 UTC

Social Media

Natera Inc shares are lower today, reflecting broader declines in the genomic sector despite earlier gains and a rebound through key moving averages.

30 июл. 2026 г., 17:51 UTC

News

Citi initiated coverage of Natera Inc with a Buy rating and a $300 price target, contributing to the stock's upward movement today.

Сравнение c конкурентами

Изменение цены

Natera Inc Прогноз

Целевая цена

By TipRanks

1.14% рост

Прогноз на 12 месяцев

Средняя 349.275 USD  1.14%

Максимум 435 USD

Минимум 270 USD

Основано на мнении 22 аналитиков Wall Street, спрогнозировавших целевые цены для Natera Inc на следующие 12 месяцев – Данные за последние 3 месяца.

Консенсус по рейтингу

By TipRanks

Активная покупка

22 ratings

20

Покупка

2

Удержание

0

Продажа

Настроения

By Acuity

23 / 339Рейтинг в Здравоохранение

Новостные настроения

Сильные свидетельства восходящего тренда

Волатильность

Ниже среднего

Объем новостей (RCV)

Ниже среднего

Финансовые показатели

Расходы на продажи и администрирование

Операционные расходы

Прибыль до уплаты налогов

Продажи

Себестоимость реализации

Валовая прибыль от продаж

Процентные расходы по долгу

EBITDA

Операционная прибыль

$

О компании Natera Inc

Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born. The company also provides Signatera, a ctDNA blood test for molecular residual disease assessment and surveillance of disease recurrence in patients previously diagnosed with cancer; Altera, a tissue based comprehensive genomic profiling test; Prospera to assess active rejection in patients who have undergone kidney, heart, and lung transplantation; and Renasight, a kidney gene panel test. In addition, it offers Constellation, a cloud-based software product that enables laboratory customers to gain access through the cloud to the company's algorithms and bioinformatics to validate and launch tests. The company offers products through its direct sales force, as well as through a network of laboratory and distribution partners. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. The company was founded in 2003 and is headquartered in Austin, Texas.
help-icon Live chat